Assessing Glycemic Control Using CGM for Women with Diabetes in Pregnancy

• Published in: Current diabetes reports Vol. 21; no. 11; p. 44
• Main Authors: O’Malley, Grenye, Wang, Ally, Ogyaadu, Selassie, Levy, Carol J.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2021; Springer Nature B.V
• Subjects: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes; Diabetes and Pregnancy (M-F Hivert and CE Powe; Diabetes Mellitus, Type 1; Diabetes, Gestational - drug therapy; Female; Glucose; Glucose monitoring; Glycemic Control; Humans; Infant, Newborn; Medicine; Medicine & Public Health; Pregnancy; Section Editors; Topical Collection on Diabetes and Pregnancy; Pregnancy; Continuous glucose monitoring; Gestational; Sensor
• ISSN: 1534-4827; 1539-0829
• DOI: 10.1007/s11892-021-01415-2

Purpose of Review Diabetes during pregnancy increases the risk of maternal and fetal complications. This article reviews the types of CGM currently available, the glucose metrics which correlate with pregnancy outcomes, endocrine organization recommendations, clinical considerations for CGM implementation, and anticipated directions for future research. Recent Findings CGM use during pregnancy is increasing, and recommendations for use have been incorporated into many organizations’ consensus guidelines. Increased time spent within a target range of 63–140 mg/dL and lower mean glucose are associated with lower risk of neonatal complications including large for gestational age infants. Use of CGM during pregnancy can detect postprandial and nocturnal hyperglycemia missed by self-monitoring of blood glucose (SMBG) which can be used for prognosis and to guide pharmacologic interventions. Summary The use of continuous glucose monitoring (CGM) during pregnancies complicated by type 1, type 2, and gestational diabetes has been shown to improve outcomes.